Minimally invasive splenectomy for thrombocytopenia associated with liver cirrhosis

被引:0
作者
Popa, M. [1 ]
Vasilescu, C. [1 ]
机构
[1] Inst Boli Digest & Transplant Hepat Fundeni, Cent Chirurg Gen & Transplant Hepat, Bucharest, Romania
关键词
minimally invasive splenectomy; liver cirrhosis; thrombocytopenia; PORTAL-VEIN THROMBOSIS; CHRONIC HEPATITIS-C; LAPAROSCOPIC SPLENECTOMY; HEPATOCELLULAR-CARCINOMA; ESOPHAGEAL-VARICES; PLUS RIBAVIRIN; VENOUS SYSTEM; DISEASE; THROMBOPOIETIN; PLATELETS;
D O I
暂无
中图分类号
R61 [外科手术学];
学科分类号
摘要
Thrombocytopenia is a common complication in patients with chronic liver disease and corelates with the severity of cirrhosis. Severe trombocytopenia can sinificantly increase the risk of spontaneous bleeding, but even if it is not symptomatic it can complicate the medical management of the cirrhotic patient by postponing diagnistic or therapeutic procedures (liver biopsy, interferon therapy, hepatocellular carcinoma resection). In consequence, numerous procedures were imagined to reverse thrombocytopenia associated with liver cirrhosis, among wich splenectomy. Due to the extreme invasiveness of the clasic approach in patients with hipersplenism (risk of bleeding, postoperative pain) especially in those with advanced cirrhosis, minimally invasive splenectomy appears to offer a safe and effective method for reversing thrombocytopenia in a highly selected group of patients with liver cirrhosis (Child A cirrhosis without other significant medical comorbid conditions). In these cases the surgical procedure is associated with low morbidity, blood loss and short hospital stay.
引用
收藏
页码:15 / 20
页数:6
相关论文
共 48 条
[21]   Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial [J].
Manns, MP ;
McHutchison, JG ;
Gordon, SC ;
Rustgi, VK ;
Shiffman, M ;
Reindollar, R ;
Goodman, ZD ;
Koury, K ;
Ling, MH ;
Albrecht, JK .
LANCET, 2001, 358 (9286) :958-965
[22]   Interferon-induced thrombocytopenia: Is it time for thrombopoietin? [J].
Martin, TG ;
Shuman, MA .
HEPATOLOGY, 1998, 28 (05) :1430-1432
[23]   Adherence to combination therapy enhances sustained response in genotyp-1-infected patients with chronic hepatitis C [J].
McHutchison, JG ;
Manns, M ;
Patel, K ;
Poynard, T ;
Lindsay, KL ;
Trepo, C ;
Dienstag, J ;
Lee, WM ;
Mak, C ;
Garaud, JJ ;
Albrecht, JK .
GASTROENTEROLOGY, 2002, 123 (04) :1061-1069
[24]   Blunted thrombopoietin response to interferon alfa-induced thrombocytopenia during treatment for hepatitis C [J].
Peck-Radosavljevic, M ;
Wichlas, M ;
Pidlich, J ;
Sims, P ;
Meng, G ;
Zacherl, J ;
Garg, S ;
Datz, C ;
Gangl, A ;
Ferenci, P .
HEPATOLOGY, 1998, 28 (05) :1424-1429
[25]  
Peck-Radosavljevic M., 2000, CAN J GASTROENTEROL, V14, p60D, DOI [DOI 10.1155/2000/617428], 10.1155/2000/617428, DOI 10.1155/2000/617428]
[26]  
PEREIRA J, 1995, AM J HEMATOL, V50, P173, DOI 10.1002/ajh.2830500305
[27]  
RATTNER DW, 1993, ARCH SURG-CHICAGO, V128, P565
[28]   SIDE-EFFECTS OF ALPHA INTERFERON [J].
RENAULT, PF ;
HOOFNAGLE, JH .
SEMINARS IN LIVER DISEASE, 1989, 9 (04) :273-277
[29]   The role of thrombopoietin in the thrombocytopenia of patients with liver cirrhosis [J].
Rios, R ;
Sangro, B ;
Herrero, I ;
Quiroga, J ;
Prieto, J .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (06) :1311-1316
[30]  
SCHMIDT KG, 1985, SCAND J HAEMATOL, V34, P39